ImmunoPrecise Antibodies Ltd. reported earnings results for the full year ended April 30, 2022. For the full year, the company reported sales was CAD 19.36 million compared to CAD 17.91 million a year ago. Net loss was CAD 16.71 million compared to CAD 7.34 million a year ago. Basic loss per share from continuing operations was CAD 0.85 compared to CAD 0.45 a year ago.